However, these approaches are largely only capable of assessing antibody reactivities to a select number of known allergenic components (typically one to a few dozen) and are frequently difficult to interpret. Importantly, the identification of novel allergenic epitopes is both costly and time-intensive; inexpensive high-throughput approaches that efficiently identify novel epitopes would therefore have great utility to inform clinical component and allergenic epitope test development.